InspireMD Inc. plans to offer and sell its common shares in an underwritten public offering.
The Israeli company also plans to grant the underwriters an overallotment option to buy additional shares.
InspireMD plans to use 15% of the proceeds to redeem the outstanding shares of its series D convertible preferred stock. It also plans to use the proceeds for research and development, capital expenditures, working capital and other general corporate purposes.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.